Medicak techniligies assesment in COVID-19

Abstract

According to official information about the coronavirus, as of May 2023, about 400 thousand people died from COVID-19 in Russia, 6.9 million people in the world. Social, as well as medical and economic aspects are associated with the COVID-19 pandemic. The main global financial resources were allocated to the provision of vaccines ($13.8 billion, 40.4%); reorganization of health systems ($4.1 billion); COVID-19 drug therapy ($3.4 billion). The costs of research, development and study of vaccines and medicines accounted for only 0.6% of total costs ($166 million). The article presents a clinical and pharmacological analysis of various medicines recommended for the treatment of infection. In these conditions, the reliability and effectiveness of national health technology assessment systems has become particularly relevant.